Print this page    •   Back to Web version of article

Putting PrEP Into Practice: Adopt an Attitude of Discovery
An Interview With Robert M. Grant, M.D., M.P.H.

By Mark Mascolini

Winter 2012

Robert M. Grant, M.D., M.P.H.

Robert M. Grant, M.D., M.P.H., Professor, Medicine, University of California, San Francisco Senior Investigator, Gladstone Institute of Virology San Francisco, California

Who Should Try PrEP?

Mascolini: For whom should US clinicians prescribe PrEP?

Grant: Broadly speaking, PrEP is for people potentially exposed to HIV infection. In the United States one key group consists of young men of color in urban centers that have an identified epidemic. PrEP candidates also include their partners, who may be women, and other people potentially at risk for acquiring HIV.

I think the most important point is that PrEP is for people who want it. Anyone who comes forward and says they're interested in finding new ways to protect themselves and their partners from HIV should receive prevention services, regardless of whether we can easily identify a risk factor. I say that because most of the language that we use about "risk groups" and "risk factors" is stigmatizing, off-putting, and insulting. It seems to me that if someone has come forward and says, look, I want PrEP, or I want to explore this, the answer should be yes. If anyone says, I want to find ways of keeping myself free of HIV, the answer should be yes.

Mascolini: Are you saying that if a man or a woman seeing a healthcare provider says they want PrEP, the provider shouldn't say, well, how many sex partners do you have, or do you use condoms consistently?

Grant: It's fine to explore these issues and to engage in such a conversation. But I think many clinicians are not prepared to have a nonjudgmental discussion about numbers of partners and sexual practices and similar issues. Clinicians need to think seriously about whether they're prepared to have a nonjudgmental conversation with a patient. If they are prepared, then by all means that kind of conversation can be useful.

This field is evolving rapidly. I think we need to help healthcare providers learn more about sexual health and ways of promoting sexual health in nonjudgmental ways. That process takes some time. In the meantime, when someone asks for prevention services, the answer should be yes.

Advertisement

Mascolini: Do you think heterosexual men and women with some risk of HIV infection are going to use PrEP in the United States?

Grant: Yes, I think they will sometimes. Certainly for heterosexual couples with one negative and one positive partner who desire pregnancy, PrEP is a very attractive option. Another alternative is suppressive therapy for the infected partner, which is also highly effective in preventing transmission.2 But sometimes the negative partner may not have complete faith in their partner's ability to take antiretroviral therapy in a fully suppressive way. In those cases PrEP becomes an additional safeguard to allow intimate sex and pregnancy while lowering the risk of HIV transmission.

Identifying heterosexuals who need HIV prevention services has been a challenge in the United States. Again, I think that if we can find less stigmatizing ways of talking about HIV and sex, people will be more willing to come forward and ask for prevention services if they need them.

Mascolini: So far PrEP clinical trials that enrolled heterosexuals took place in Africa.3-5 Can US and European clinicians be sure PrEP will work in heterosexual men and women outside Africa?

Grant: Yes. The Partners PrEP study3 and the TDF2 study4 both demonstrated that oral TDF/FTC is highly effective in heterosexual populations. Both of those studies were done in Africa, but the biology of heterosexual transmission is very similar around the world. I think that in heterosexual populations, as with gay men, adherence to PrEP is very important. It will not work if it is not used, and we've seen that in our research.1,3-5 PrEP will fail if it's not used sufficiently to attain detectable drug levels in the body.

Mascolini: iPrEx had a small contingent of transgender participants, and your iPrEx abstract for the 2011 IAS meeting showed no protection of transgender participants.6 Should clinicians consider PrEP for male-to-female transgender people?

Grant: I think they can consider it. In iPrEx we found that transgender women had detectable drug in their blood less frequently than other subgroups. We believe the trans subgroup in our study had more difficulty with adherence and that likely explains the lack of protective effect in that subgroup.

Importantly, there were insufficient numbers of trans women in iPrEx to know whether PrEP can work for them, so we're not sure yet whether PrEP efficacy is similar in trans women compared with gay men. But I think PrEP with tenofovir/emtricitabine [TDF/FTC, Truvada] is an option for trans women. Certainly, they should be aware that there's less information available about how well it works for them and that adherence was particularly challenging for trans women in iPrEx, we think for social reasons.

Everyone should realize that PrEP is highly effective if taken, but it is harder to take than people imagine. It does require taking a pill a day. People have to be organized to build that into their lives. They have to have an ongoing relationship with their healthcare provider.

Mascolini: Do you have a sense of whether many clinicians are starting to prescribe PrEP in the United States?

Grant: I think it's just beginning. As I go around the United States giving talks, typically there's one clinician in every room in virtually every city I've visited who is currently prescribing PrEP. But it really hasn't taken off as a common practice. I think providers are still trying to learn how best to use it and how best to inform people's decisions about whether PrEP is right for them.

Mascolini: When you give these talks around the country, what are the primary PrEP concerns your audiences ask about?

Grant: They're concerned about who should be offered PrEP, and I usually emphasize that people who want it should be offered PrEP. People's initiative is really the key thing to nurture at this point. We're trying to build a prevention initiative across the country so that we can see an AIDS-free generation.

Clinicians are interested in long-term as well as shortterm side effects, as well as tolerance issues. They want to know when to start and when to stop PrEP. Does it have to be taken daily? Are there alternative regimens that are just as good? And then the practical questions: Who's going to pay for it and how can it be made available within our existing healthcare system?

Mascolini: Are third-party payers paying for PrEP?

Grant: I believe they are all paying for it. The payers in the United States have decided not to require HIV testing results before paying for antiretroviral medications, and they do realize this means they are paying for PrEP. Preventing HIV infection potentially saves 40 years or more of antiretroviral therapy costs. People who are taking antiretroviral therapy for infection still have an excess risk of cancer and heart disease, which obviously cause a lot of suffering, but they're also very expensive conditions to treat.

Insurance companies are very happy to see money spent on HIV prevention -- it saves them money in the end. So generally they've been supportive of PrEP. The payers are not advertising that they have positive policies regarding PrEP, but they certainly have decided to pay for it the way they have been so far.

Mascolini: What are you telling providers about the potential risk of side effects with Truvada PrEP and what they should be watching for if they decide to prescribe it?

Grant: The side effects that we see most frequently are short-term side effects, and it's important to be aware of them. Trials indicate that somewhat less than 1 in 10 uninfected people who start Truvada PrEP will have some sort of symptom -- nausea, abdominal cramping, dizziness, or headache. Typically these problems occur in the first week or 2 of PrEP use, and they resolve if people continue taking their medications. Some reassurance through that first period can help people decide whether they want to continue trying to take PrEP. It's useful to have a check-in visit after 2 or 4 weeks of PrEP use just to see how it's going. At that visit, clinicians can see whether people decided to actually take the pill and whether those who did are having that start-up syndrome, which is reminiscent of the startup syndrome that may occur when people start taking antiretroviral drugs for treatment of HIV. Making PrEP users aware that this syndrome can occur and that it usually resolves spontaneously is important for early adherence.

There were no excess moderate to severe side effects in people taking PrEP versus those taking placebo in the phase 3 trials.1,3-5 We did see that a small number of individuals taking Truvada PrEP had elevations in their serum creatinine, which is an indicator of renal function. We agree with the CDC's recommendation that serum creatinine should be monitored in people taking PrEP.7,8

Advertisement

If serum creatinine increases more than 50% above baseline or if serum creatinine is abnormally high, the first thing to do is to recheck the blood test, because most serum creatinine elevations will resolve without stopping the drugs. If there's a confirmed increase in serum creatinine, we do recommend that PrEP be stopped and that serum creatinine be allowed to return to normal. If it does return to normal, PrEP can be restarted with careful monitoring.

We saw elevated serum creatinine in about 1 in 200 PrEP users in iPrEx.1 It's rare, but if a clinician is writing prescriptions for 200 PrEP users, they may see 1 or 2 people who have confirmed elevations in serum creatinine.

Finally we saw an average 1% loss in bone mineral density in people taking Truvada PrEP.1 This average change in bone mineral density occurred in the first 6 months of PrEP and did not progress with ongoing exposure to PrEP, and it was not associated with an excess in bone fractures. The FDA package insert indicates that the preventive use of these drugs can cause a small decrease in bone mineral density, and people who have risk factors for osteoporosis might consider DEXA scanning during PrEP use.

We did not see any change in fat distribution in HIVnegative people taking Truvada PrEP in iPrEx.1 There had been concerns that lipodystrophies might occur with Truvada PrEP -- that we might see the kinds of fat redistribution observed in people taking antiretrovirals for HIV treatment. But we did not see anything like that in people taking PrEP. Risk of intermittent PrEP, and research priorities

Mascolini: Is there a danger that people will use Truvada PrEP as a presex or morning-after pill?

Grant: We think Truvada PrEP is most useful when it's taken daily, so we recommend that people who want to protect themselves by using PrEP should take it daily. There is interest in intermittent dosing, but we emphasize that one pill is not enough for protection: Protective concentrations of the drugs continue to increase over the first 21 days of use, so if people want the maximum level of protection they should take it daily.

Will people try to take this in a more casual way? I think it's too early to know. We do know and have published in Science Translational Medicine that people in iPrEx were protected by PrEP even though adherence was less than perfect.9 The drug concentrations that we observed in iPrEx were commensurate with 3 to 7 doses per week, yet we did see high levels of protection in all people who had detectable levels of drug in their blood, even if drug levels were relatively low. Although people should try to take Truvada PrEP daily, there is some forgiveness for missing some doses, especially if people are taking it daily. If they try to take it just before and after sex, that may provide some protection, but there's no forgiveness if they miss the preexposure dose or the postexposure dose or if they take it a little late -- the regimen becomes fragile if people try to take it just pre- and postexposure.

Mascolini: What are the priorities for ongoing PrEP research?

Grant: The main priority is how to make PrEP easier to use. We do have studies in the field looking at nondaily Truvada regimens: Can people take it pre- and postintercourse?10 Can they take it twice a week with a postintercourse boost?11 [See "Prospects for Intermittent PrEP Dosing" in the article preceding this interview.] PrEP formulations that can be used in different ways are important to develop, perhaps an injection once a month.

Not everyone was able to tolerate Truvada in PrEP trials. The vast majority of people who took Truvada PrEP could tolerate it, but some people didn't. So alternative antiretrovirals, possibly maraviroc or raltegravir, should also be explored. Some antiretrovirals, such as the nonnucleoside dapivirine, have very long half-lives. Discovering whether they can be used as PrEP is also very important.


Key Findings From the iPrEx Study of TDF/FTC PrEP1
  • 2499 men and transgender women who have sex with men enrolled in Peru, Ecuador, South Africa, Brazil, Thailand, and the United States
  • Participants randomized to once-daily TDF/FTC or placebo
  • Half of participants (47% TDF/FTC, 53% placebo) 18 to 24 years old
  • Almost three quarters of participants (72% TDF/FTC, 73% placebo) Hispanic
  • About 10% of participants (9% TDF/FTC, 10% placebo) from US (San Francisco or Boston)
  • Average number of sex partners in last 12 weeks: 18
  • Unprotected receptive anal intercourse in past 12 weeks: 59% TDF/FTC, 60% placebo
  • Any grade 3 or 4 adverse event: 12% TDF/FTC, 13% placebo
  • Elevated creatinine: 2% TDF/FTC, 1% placebo
  • Overall decrease in HIV acquisition risk with TDF/FTC: 44%
  • Decrease in HIV acquisition risk with TDF/FTC with at least 50% pill use*: 50%
  • Decrease in HIV acquisition risk with TDF/FTC with at least 90% pill use*: 73%
  • Decrease in HIV acquisition risk with detectable TDF/FTC in plasma: 92%
  • No significant between-group difference in protection on the basis of region, race or ethnic group, male circumcision, education level, alcohol use, or age

* Determined by study-drug dispensation and returns.

† Decrease 95% after adjustment for reported unprotected receptive anal intercourse.


Mascolini: What are you looking for in iPrEx OLE -- the open-label extension of the iPrEx trial?

Grant: iPrEx OLE is fully enrolled with 1770 individuals. We offer PrEP to everyone, and we follow them whether or not they choose to protect themselves with PrEP. We are looking at who chooses to take PrEP and who chooses not to, and we will measure HIV infection rates in both groups. Over the 1.5 years that we will follow this cohort, we are hoping that all 1770 participants remain free of HIV, regardless of how they chose to protect themselves from HIV.

Among people who start PrEP in this open-label format, we want to learn how well they adhere to the regimen and how their sexual practices might change: Do they stop using condoms? Do they have more sexual partners? Or rather do they focus more on intimacy with one or a few partners? We see that people do change their sexual practices and their sexual goals when they start PrEP, but interestingly the change is often in the direction of seeking more intimacy with fewer partners rather than the opposite. Our overall goal is to discover what people will do when PrEP becomes a real opportunity accompanied with real information about what the pill is, how effective it can be, and how safe it is.

Mascolini: Is there anything we didn't discuss that you think prescribers or PrEP candidates should know?

Grant: PrEP is a new approach. We're still discovering a lot about it, so having an attitude of discovery with potential PrEP users is appropriate. Let's explore for whom this is a good intervention, how long they want to take it, and how well they can achieve their goals by PrEP or alternative means. I think an attitude of exploration is appropriate, and I think it's equally important to move away from stigmatizing language. We need to stop thinking in terms of "risk groups" and "risk behavior" and start appreciating people for who they are and for their desires to remain healthy and socially engaged.


References

  1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
  2. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
  3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
  4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
  5. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
  6. Grant R, McMahan V, Liu A, et al. Completed observation of the randomized placebo-controlled phase of iPrEx: daily oral FTC/TDF pre-exposure HIV prophylaxis among men and trans women who have sex with men. 6th IAS Conference on HIV Pathogenesis and Treatment. July 17-20, 2011. Rome. Abstract WELBC04.
  7. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR. 2011;60:65-68.
  8. Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR. 2012;61:586-589.
  9. Anderson PL, Glidden DV, Liu AI, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra125.
  10. ClinicalTrials.gov. On demand antiretroviral pre-exposure prophylaxis for HIV infection in men who have sex with men (IPERGAY).
  11. ClinicalTrials.gov. The ADAPT study: use of emtricitabine and tenofovir disoproxil fumarate for pre-exposure prophylaxis (PrEP).




This article was provided by The Center for AIDS. It is a part of the publication Research Initiative/Treatment Action!. You can find this article online by typing this address into your Web browser:
http://www.thebodypro.com/content/72565/putting-prep-into-practice-adopt-an-attitude-of-di.html

General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.